Current therapeutic development is focused on targeting molecular mechanisms, and this has resulted in significant improvements in outcome for several cancer types (for example, crizotinib for EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)). Here, ALK is linked to non-small cell lung carcinoma.